BioMarin’s Bienaimé To Retire With Sales And Earnings Growth On Track

 
• By Jessica Merrill

Genentech CEO Alexander Hardy will succeed Jean-Jacques Bienaimé, who has led the rare disease specialist for 18 years. Gene therapy Roctavian has gotten off to a slow commercial start.

BioMarin CEO Jean-Jacques Bienaimé • Source: BioMarin (Richard Morgenstein)

More from Leadership

More from Scrip